Purpose

Proton therapy is becoming an increasingly popular cancer treatment modality due to the proton's physical advantage in that it deposits the majority of its energy at the distal end of its track where the tumor is located. The proton range in a material is determined from the stopping power ratio (SPR) of the material. However, SPR is typically estimated based on a computed tomography (CT) scan which can lead to range estimation errors due to the difference in x-ray and proton interactions in matter, which can preclude the ability to utilize protons to their full potential. Applications of magnetic resonance imaging (MRI) in radiotherapy have increased over the past decade and using MRI to calculate SPR directly could provide numerous advantages. The purpose of this study was to develop a practical implementation of a novel multimodal imaging method for estimating SPR and compare the results of this method to physical measurements in which values were computed directly using tissue substitute materials fabricated to mimic skin, muscle, adipose, and spongiosa bone.

Methods

For both the multimodal imaging method and physical measurements, SPR was calculated using the Bethe-Bloch equation from values of relative electron density and mean ionization potential determined for each tissue. Parameters used to estimate SPR using the multimodal imaging method were extracted from Dixon water-only and (¹ H) proton density-weighted zero echo time MRI sequences and CT, with both kVCT and MVCT used separately to evaluate the performance of each. For comparison, SPR was also computed from kVCT using the stoichiometric method, the current clinical standard.

Results

Results showed that our multimodal imaging approach using MRI with either kVCT or MVCT was in close agreement to SPR calculated from physical measurements for the four tissue substitutes evaluated. Using MRI and MVCT, SPR values estimated using our method were within 1% of physical measurements and were more accurate than the stoichiometric method for the tissue types studied.

Conclusions

We have demonstrated the methodology for improved estimation of SPR using the proposed multimodal imaging framework.

Objective. Kilovoltage computed tomography (kVCT) is the cornerstone of radiotherapy treatment planning for delineating tissues and towards dose calculation. For the former, kVCT provides excellent contrast and signal-to-noise ratio. For the latter, kVCT may have greater uncertainty in determining relative electron density (ρe) and proton stopping power ratio (SPR). Conversely, megavoltage CT (MVCT) may result in superior dose calculation accuracy. The purpose of this work was to convert kVCT HU to MVCT HU using deep learning to obtain higher accuracyρeand SPR.Approach. Tissue-mimicking phantoms were created to compare kVCT- and MVCT-determinedρeand SPR to physical measurements. Using 100 head-and-neck datasets, an unpaired deep learning model was trained to learn the relationship between kVCTs and MVCTs, creating synthetic MVCTs (sMVCTs). Similarity metrics were calculated between kVCTs, sMVCTs, and MVCTs in 20 test datasets. An anthropomorphic head phantom containing bone-mimicking material with known composition was scanned to provide an independent determination ofρeand SPR accuracy by sMVCT.Main results. In tissue-mimicking bone,ρeerrors were 2.20% versus 0.19% and SPR errors were 4.38% versus 0.22%, for kVCT versus MVCT, respectively. Compared to MVCT,in vivomean difference (MD) values were 11 and 327 HU for kVCT and 2 and 3 HU for sMVCT in soft tissue and bone, respectively.ρeMD decreased from 1.3% to 0.35% in soft tissue and 2.9% to 0.13% in bone, for kVCT and sMVCT, respectively. SPR MD decreased from 1.8% to 0.24% in soft tissue and 6.8% to 0.16% in bone, for kVCT and sMVCT, respectively. Relative to physical measurements,ρeand SPR error in anthropomorphic bone decreased from 7.50% and 7.48% for kVCT to <1% for both MVCT and sMVCT.Significance. Deep learning can be used to map kVCT to sMVCT, suggesting higher accuracyρeand SPR is achievable with sMVCT versus kVCT.

Simultaneous positron emission tomography and MRI (PET/MRI) is a technology that combines the anatomic and quantitative strengths of MR imaging with physiologic information obtained from PET. PET and computed tomography (PET/CT) performed in a single scanning session is an established technology already in widespread and accepted use worldwide. Given the higher cost and complexity of operating and interpreting the studies obtained on a PET/MRI system, there has been question as to which patients would benefit most from imaging with PET/MRI versus PET/CT. In this article, we compare PET/MRI with PET/CT, detail the applications for which PET/MRI has shown promise and discuss impediments to future adoption. It is our hope that future work will prove the benefit of PET/MRI to specific groups of patients, initially those in which PET/CT and MRI are already performed, leveraging simultaneity and allowing for greater degrees of multiparametric evaluation.

Level of evidence

5 Technical Efficacy: Stage 5 J. Magn. Reson. Imaging 2017;46:1247-1262.